Research is focused on reducing over-activation of the intracellular inflammatory cascade. By therapeutically engaging with this process, it is possible to reduce the release of inflammatory cytokines and other inflammatory molecules and so ease inflammation
Carocell Bio’s therapeutic molecules are short proteins (“peptides”) that are highly selective for mitogen-activated protein kinase (MAPK, p38α), an important component in this intracellular inflammation cascade. Combining these peptides with an established nano-polymer delivery system enhances delivery into the cells. The treatments are designed to be delivered topically rather than systemically and the peptides are simply broken down into amino acids so they are likely to provide a much safer option compared with existing therapies
Contact
Email: contact@carocellbio.com
UK: +44 (0) 161 532 8751
US: +1 307 409 5778
Information
USA Office
Carocell Bio, Inc.
500 Delaware Avenue
Ste#1, 1960
Wilmington
DE 19899
USA
UK Office
Carocell Bio Ltd.
Brooks Drive
Cheadle Royal Business Park
Manchester
SK8 3TD
Copyright Carocell Bio Ltd. ©2020